Page 8 - Rx Communications Group News Today : Breaking News, Live Updates & Top Stories | Vimarsana

NeuroBo Pharmaceuticals Submits IND Application to the FDA for a Phase 1 Clinical Trial of DA-1726 for the Treatment of Obesity

CAMBRIDGE, Mass., Dec. 28, 2023 /PRNewswire/ NeuroBo Pharmaceuticals, Inc. , a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that it has.

United kingdomMichael millerMarshallh woodworthDonga st coPrnewswire neurobo pharmaceuticals incNeurobo pharmaceuticalsRx communications groupNeurobo pharmaceuticals incDrug administrationInvestigational new drugHyung heon kimChief executive officerNon alcoholic steatohepatitisPrivate securities litigation reform act

ReShape Lifesciences® Engages Maxim Group LLC To Identify Strategic M&A Partnership Alternatives

IRVINE, Calif., Dec. 20, 2023 ReShape Lifesciences Inc. , the premier physician-led weight loss and metabolic health-solutions company, today announced that it has engaged Maxim Group LLC, to.

United statesPaulf hickeyMichael millerRx communications groupMaxim groupGlobenewswire incExchange commissionLifesciences incShape lifesciencesSecurities rulemaking boardReshape lifesciencesDiabetes bloc stim neuromodulationShape lifesciences contactChief executiveRelations contact

NeuroBo to Participate in Investor Conferences in December

BOSTON, Dec. 1, 2023 /PRNewswire/ NeuroBo Pharmaceuticals, Inc. , a clinical-stage biotechnology company focused on the transformation of cardiometabolic diseases, today announced that Hyung.

United statesRobert homolkaMichael millerMarshallh woodworthPrnewswire neurobo pharmaceuticals incLife science virtual investor forumDonga st coNeurobo pharmaceuticalsRx communications groupNeurobo pharmaceuticals incHyung heon kimChief executive officerActing chief financial officerSenior vice presidentClinical operationsInvestor summit virtual

Immunic Receives Notice of Allowance for United States Patent Protecting Vidofludimus Calcium s Dosing Regimens in Multiple Sclerosis

/PRNewswire/ Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for.

United statesEdna kaplanDaniel vittJessica breuPaula schwartzPrnewswire immunic incImmunic incRx communications groupTrademark officeExchange commissionFundamental new patent covers treatmentMultiple sclerosis intoVidofludimus calciumMultiple sclerosisUnless extended furtherProtecting specific dose strength

EQS-News: Immunic, Inc : Immunic Receives Notice of Allowance for United States Patent Protecting Vidofludimus Calcium s Dosing Regimens in Multiple Sclerosis

EQS-News: Immunic, Inc : Immunic Receives Notice of Allowance for United States Patent Protecting Vidofludimus Calcium s Dosing Regimens in Multiple Sclerosis
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

Rheinland pfalzUnited statesEdna kaplanJessica breuStates patentprotecting vidofludimusDaniel vittPaula schwartzImmunic incDistribution servicesExchange commissionRx communications groupTrademark officeReceives noticeDosing regimensMultiple sclerosisNew patent covers treatment